NCT04897412View on ClinicalTrials.gov

A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2)

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

February 22, 2023

Study Completion Date

March 22, 2023

Conditions
Subcutaneous Fat
Interventions
DRUG

CBL-514 Injection

Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.

OTHER

Placebo

Sodium Chloride (0.9% NaCl) placebo for injection

Trial Locations (5)

3141

Investigational site 5, Melbourne

37215

Investigational site 3, Nashville

60611

Investigational site 1, Chicago

68144

Investigational site 2, Omaha

78759

Investigational site 4, Austin

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT04897412 - A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) | Biotech Hunter | Biotech Hunter